- /
- Supported exchanges
- / US
- / ABVX.NASDAQ
Abivax SA American Depositary Shares (ABVX NASDAQ) stock market data APIs
Abivax SA American Depositary Shares Financial Data Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abivax SA American Depositary Shares (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Abivax SA American Depositary Shares data using free add-ons & libraries
Get Abivax SA American Depositary Shares Fundamental Data
Abivax SA American Depositary Shares Fundamental data includes:
- Net Revenue: 4 920 K
- EBITDA: -254 004 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Abivax SA American Depositary Shares Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-05-22
- EPS/Forecast: -0.81
Get Abivax SA American Depositary Shares End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abivax SA American Depositary Shares News
New
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. ...
3 Soaring Stocks That May Have More Upside Ahead
Key Points Abivax's shares could rise even further as it advances a candidate poised to disrupt a large market. Krystal Biotech's strong financial results and deep pipeline make its prospects attract...
3 Soaring Stocks That May Have More Upside Ahead
"Buy low" is a common investing phrase that some people may interpret as "buy after a pullback." However, even near all-time highs, a stock can be at a "low" point, provided there are good reasons to ...
Abivax: Wall Street Catches Up to the Data
Key Points Interested in Abivax SA Sponsored ADR? Here are five stocks we like better. Abivax shares rose more than 40% in a month after positive Phase 3 trial results for Obefazimod, a proposed ulce...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.